State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Clin Transl Oncol. 2024 Feb;26(2):326-337. doi: 10.1007/s12094-023-03266-7. Epub 2023 Jul 4.
Hepatocellular carcinoma (HCC) caused by HBV, HCV infection, and other factors is one of the most common malignancies in the world. Although, percutaneous treatments such as surgery, ethanol injection, radiofrequency ablation, and transcatheter treatments such as arterial chemoembolization are useful for local tumor control, they are not sufficient to improve the prognosis of patients with HCC. External interferon agents that induce interferon-related genes or type I interferon in combination with other drugs can reduce the recurrence rate and improve survival in HCC patients after surgery. Therefore, in this review, we focus on recent advances in the mechanism of action of type I interferons, emerging therapies, and potential therapeutic strategies for the treatment of HCC using IFNs.
由 HBV、HCV 感染和其他因素引起的肝细胞癌（HCC）是世界上最常见的恶性肿瘤之一。尽管经皮治疗，如手术、乙醇注射、射频消融和经导管治疗，如动脉化疗栓塞，对于局部肿瘤控制是有用的，但不足以改善 HCC 患者的预后。外源性干扰素制剂通过诱导干扰素相关基因或 I 型干扰素与其他药物联合应用，可以降低 HCC 患者手术后的复发率并改善其生存。因此，在这篇综述中，我们重点介绍了 I 型干扰素的作用机制、新兴疗法的最新进展，以及利用 IFNs 治疗 HCC 的潜在治疗策略。
